Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings

Cancer research · Hepatocellular carcinoma

After a median follow-up of 21 months, median overall survival was not reached; estimated survival was 93.8% at 1 year and 80.0% at 3 years.

This retrospective cohort study of 134 adults with hepatocellular carcinoma (HCC) managed at a Center of Clinical Excellence (CCE) in Bogotá, Colombia, describes sociodemographic and clinical characteristics, treatment patterns, and overall survival. The most common etiology was metabolic dysfunction-associated steatotic liver disease (MASLD, 34.4%). Most patients were diagnosed at early BCLC stages 0/A (64.2%). Ablation and transarterial chemoembolization were the most frequently used treatments, and liver transplantation was performed in 9.7% of patients. After a median follow-up of 21 months, median overall survival was not reached; estimated survival probabilities were 93.8% at 1 year and 80.0% at 3 years. These findings provide real‑world data on HCC care in a middle‑income setting and highlight the relevance of structured, multidisciplinary care programs.

This study demonstrates that patients with HCC receiving care in a structured Center of Clinical Excellence in Colombia achieve survival outcomes comparable to or better than those reported in high‑income settings, underscoring the feasibility and clinical value of multidisciplinary, guideline‑concordant management in a middle‑income context.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals